Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License
Share
Why It Matters
Heron Therapeutics got the right to sell new medicines in America. They will pay money when goals are hit and share profits.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.